Skip to main content
Tech.euFundingExplorerBeta

Amal Therapeutics

Exited

Developing and progressing therapeutic cancer vaccines

Amal Therapeutics has raised €2.8M across 1 funding round from 3 investors, most recently a Series A round in Mar 2016. Based in Geneva, Switzerland; founded 2012; active in Healthtech. Acquired by Boehringer Ingelheim in 2019. Data as of 28 Oct 2026.

Geneva, SwitzerlandFounded 2012amaltherapeutics.com ↗
Healthtech
← All companies
Total raised
€2.8M
€2,800,000
Funding rounds
1
Investors
3
distinct backers
Active since
2016-03
latest 2016-03

Funding by year

EUR raised per year
Amal Therapeutics — funding by year — interactive chart.
Data table
Amal Therapeutics — funding by year
2016€2.8M

Funding rounds

1 round
DateStageAmountInvestors
2016-03-01Series A€2.8MBoehringer Ingelheim Venture Fund,High-Tech Gründerfonds (HTGF),VI PartnersView deal →

Exit

Type
acquisition
Date
Nov 2019
Value
€325M
Acquiror
Boehringer Ingelheim (Germany)

Investors

3
Boehringer Ingelheim Venture FundHigh-Tech Gründerfonds (HTGF)VI Partners

Related news

Similar companies

same sector or country

Global coverage: FundingData